- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04767022
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Chinese Patients With Coronary ISR
A Prospective, Multicenter, Randomized Controlled Trials to Evaluate the Safety and Efficacy of Genoss® DCB Versus SeQuent® Please NEO in Patients With Coronary In-stent Restenosis (ISR)
The purpose of this study is to evaluate the safety and efficacy of Genoss® DCB by demonstrating non-inferiority in patients with in-stent restenosis (ISR) compared with a product of the same category (Sequent® Please NEO).
The experimental group was treated with Genoss® DCB, and the control group was treated with SeQuent® Please NEO.
In this study, the end point of 9 months after procedure was used as the main endpoint to evaluate the efficacy of Paclitaxel coated PTCA balloon catheter. The safety of the catheter was evaluated by cardiovascular adverse events.
Study Overview
Status
Conditions
Detailed Description
In a randomized controlled trials to compare with the same-category medical device (Sequent® Please NEO), 224 patients with in-stent restenosis (ISR) were recruited from a total of 13 institutions, and the enrolled subjects were 1: 1 through randomization. The ratio was assigned to the test group(Genoss® DCB) and the control group(SeQuent® Please NEO), and each of the test or control devices was assigned to receive the procedure.
All patients were followed up 30 days, 6 months, 9 months, 1 year and 2 years after procedure, and angiographic follow-up was performed 9 months after procedure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Department of Cardiology, First Affiliated Hospital of Air Force Medical University of Chinese PLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subject related inclusion criteria
- Age≥18 years old & ≤80 years old.
- Patients with stable angina pectoris, unstable angina pectoris, stable acute myocardial infarction or confirmed silent myocardial ischemia.
- Patients who can understand the purpose of the study and voluntarily participate in and sign informed consent.
- It is suitable for patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Desease related inclusion criteria
- The target lesions were in stent restenosis: Mehran type I, II and III stenosis.
- The stenosis rate of target lesion diameter was more than 70%, or more than 50%, accompanied by objective evidence of ischemia (such as stress electrocardiogram, myocardial perfusion imaging, FFR, etc.)
- The reference vessel diameter of the target lesion was 2.0-4.0 mm, and the target lesion length was less than or equal to 26 mm.
- It is expected that no more than two drug balloons will be used in each subject, and each target lesion can be covered by one drug balloon.
- At most 2 primary lesions need interventional treatment, and the distance from the target lesion is more than or equal to 10 mm, and can be successfully treated before the intervention of the target lesion.
Exclusion Criteria:
Subject related exclusion criteria
- A woman who is pregnant, lactating, or planning a pregnancy.
- Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or history of cerebral hemorrhage, subarachnoid hemorrhage, active peptic ulcer and gastrointestinal bleeding within 3 months before operation.
- Patients who are known to be allergic to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, paclitaxel, or have contraindications to aspirin, clopidogrel or ticagrelor.
- Patients with acute myocardial infarction within 1 week before operation.
- Patients with Takayasu arteritis.
- Left ventricular ejection fraction ≤ 30%.
- Acute or chronic renal insufficiency (serum creatinine > 2.0mg/dl or 178 μ mol / L).
- Patients with life expectancy less than 1 year.
- Patients participating in clinical trials of other drugs or medical devices.
- According to the researcher's judgment, the patient's clinical condition is not suitable for this study, or the patient is expected to be unable to complete the follow-up study according to the protocol.
Disease related exclusion criteria
- The target lesion was total occlusion (Mehran type IV).
- The target and non target lesions were left main artery lesions.
- The target lesions were ostial, pontine and bifurcated lesions with branch diameter ≥ 2.5mm.
- Three vessel disease requiring treatment.
- More than 3 lesions (including target lesions and non target lesions) need to be treated in target vessels.
- ISR lesions intervened within 6 months before operation.
- Angiography confirmed thrombus in the target vessel.
- The target vessel is severely calcified, tortuous and angulated, so it is expected that the drug balloon catheter will not pass successfully.
- The lesions that could not be pre dilated successfully were grade C or above dissection after pre dilation, or residual stenosis > 30%, or TIMI blood flow < grade III.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Genoss® DCB
Paclitaxel Coated PTCA Balloon Catheter
|
Drug Coated Balloon
|
Active Comparator: SeQuent® Please NEO
Paclitaxel Coated PTCA Balloon Catheter
|
Drug Coated Balloon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-segment late lumen loss after percutaneous coronary intervention in patients with ISR
Time Frame: Follow-up angiography at 9 months after procedure
|
In-segment late lumen loss between test group(Genoss DCB) and control group(Sequent Please) evaluated by quantitiative coronary analysis in patients with ISR
|
Follow-up angiography at 9 months after procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ling Tao, Department of Cardiology, First Affiliated Hospital of Air Force Medical University of Chinese PLA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- CSP-DS1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)
-
Genoss Co., Ltd.CompletedCoronary Artery DiseaseKorea, Republic of
-
Advanced NanoTherapiesMonash University; Cardiovascular Research Foundation, New York; Cogent Technologies...Recruiting
-
C. R. BardCompletedArteriosclerosis | Atherosclerosis | Vascular DiseaseGermany, Belgium
-
Boston Scientific CorporationActive, not recruiting
-
B. Braun Medical International Trading Company...UnknownSmall Vessel DiseaseChina
-
Boston Scientific CorporationActive, not recruitingCoronary Artery DiseaseJapan
-
Airiver Medical, Inc.RecruitingChronic RhinosinusitisParaguay
-
Genoss Co., Ltd.Completed
-
Boston Scientific CorporationActive, not recruitingChinese Patients Treated With Agent DCBTaiwan, Hong Kong, Singapore
-
Airiver Medical, Inc.Libra MedicalRecruitingCentral Airway ObstructionGeorgia